真红细胞增多症用药的注意事项(国外英文资料).docVIP

真红细胞增多症用药的注意事项(国外英文资料) The purpose of PV therapy is to reduce the risk of thrombosis and bleeding. Minimizing the risk of converting to acute leukemia and bone marrow fibrosis; Treatment of possible complications, including thrombosis, bleeding and itching; (4) pregnancy treatment In aspirin can reduce the incidence of thrombosis, PV patients prompts platelets play a key role in thrombosis, also affect the incidence of bone marrow fibrosis. Thrombosis is a common complication and the cause of death, PV clearly and complete blood count, especially Hct and platelet count associated anomalies, the atherosclerosis risk factors, including hyperlipidemia and hypertension. In recent years, atherosclerosis therapy has recommended the use of antihypertensive drugs to maintain normal blood pressure and the use of statin drugs. Acute thrombosis treatment and drug prevention of acute thrombosis events shall be handled according to the present guidelines, the analysis of specific risk factors, control the Hct and platelet count in the ideal level. Low-dose aspirin for secondary prevention in patients with hematology normal atherosclerosis is clearly beneficial, but whether it can help prevent similar complications occurred in patients with MPD is controversial, because studies have confirmed that aspirin can cause bleeding patients with bleeding tendency. Then in ET patients two studies proved that low-dose aspirin (100 mg  d) security (if platelet 1000 x 109  L, and no history of bleeding), and may have the effect that reduce arterial thrombosis complications. The recent ECLAP study also supports the safety and effectiveness of aspirin in preventing the formation of PVS. Unlike aspirin, the present risk benefit analysis shows that the primary prevention of thrombosis, such as the Chinese law, does not work. In the case of secondary prevention of venous thromboembolism, it is not clear whether the short-term or long-term treatment of Chinese law should be given. This is clea